Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06752668Phase 2Recruiting

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Role: lead

NCT07096674Phase 2Recruiting

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Role: lead

NCT07413666Phase 1Recruiting

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

Role: lead

NCT07082829Phase 1Recruiting

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Role: lead

NCT05821777Phase 1Terminated

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Role: lead

All 5 trials loaded